Introduction
In the era of “fast-track’ liver transplantation (LT), neuromuscular
blockade (NMB) antagonists such as neostigmine or sugammadex are used to
achieve the restoration of neuromuscular function. While sugammadex
reverses NMB faster than neostigmine, it has been shown to prolong
prothrombin time (PT) and activated thromboplastin time (aPTT). However,
this agent’s impact on coagulation during LT is not understood. We
compare bleeding risk associated with sugammadex versus neostigmine
during liver transplantation.